Medicare muscle and market moves: health insurers split as humana rockets, elevance stalls
The gist
America’s top health insurers are sprinting in opposite directions as Humana rockets ahead on Medicare Advantage while Elevance stumbles with shrinking membership.
What to know
- Humana’s Q1 revenue jumped 23.5% to $39.65B—fueling a 56% stock surge—thanks to its Medicare Advantage focus.
- Elevance Health flexed $198.3B in annual revenue and a 26.5% five-year ROIC, but its customer base shrank 1.1% annually over two years.
- CVS Health and Centene wowed Wall Street with strong Q1 beats and stock gains, while Cencora and Cigna failed to impress despite topline growth.
Elevance's Scale vs. Shrinking Base
Elevance Health’s massive revenue and industry-leading ROIC are undercut by a steady customer exodus, raising red flags about whether operational strength can offset eroding market share.
Elevance Health leverages its massive scale, generating $198.3 billion in revenue over the past 12 months, to secure significant economies of scale that enhance negotiating power with suppliers and reduce per-unit costs. This operational heft is crucial in the volume-driven, low-margin health insurance sector, underpinning the company’s strong market position. However, despite these advantages, Elevance faces a persistent challenge with a declining customer base, which has shrunk by an average of 1.1% year-over-year over the last two years, raising concerns about its product competitiveness and market saturation.
Elevance Health’s operational efficiency is further highlighted by its impressive five-year average Return on Invested Capital (ROIC) of 26.5%, placing it among the top performers in healthcare. This metric reflects effective management and the company’s ability to capitalize on profitable growth opportunities, balancing scale with capital discipline to sustain long-term value creation.
Humana’s Medicare Advantage Dominance
Humana’s Medicare Advantage focus has not only fueled record-breaking growth and a soaring stock price, but also left rivals trailing as its business model captures outsized market share and investor optimism.
Humana's Q1 revenue surged 23.5% year over year to $39.65 billion, driven predominantly by its Medicare Advantage plans, which account for over 80% of its revenue through federal government contracts. This strong operational focus on senior health insurance has solidified Humana's competitive positioning within the sector, as evidenced by its ability to beat both quarterly and full-year EPS estimates, underscoring robust financial discipline and market strength.
Investor confidence in Humana's Medicare Advantage-driven growth strategy is reflected in its remarkable 56% stock price appreciation post-Q1 earnings, with shares trading above $358. This bullish sentiment is further supported by the company's dominant market presence, serving approximately 17 million members and generating $137.3 billion in revenue, alongside a forward P/E ratio of 35.7x, signaling expectations for continued above-average growth.
Humana's financial trajectory outpaces its peers, with a two-year annual revenue growth rate of 13.6% exceeding the health insurance sector average and projected growth accelerating to 19.4% over the next 12 months. This momentum highlights the effectiveness of its Medicare Advantage-centric business model in capturing expanding market share and driving sustainable long-term value.
Winners and Losers in Q1 Healthcare
CVS and Centene’s operational outperformance sharply contrasts with Cencora and Cigna’s stock stumbles, revealing how scale, execution, and forward outlook are redrawing the health insurance leaderboard.
CVS Health emerged as a dominant force in Q1 2026, leveraging its integrated healthcare platform to deliver a 6.2% year-over-year revenue increase to $100.4 billion and a notable adjusted EPS rise to $2.57. This growth was fueled by a robust Health Care Benefits segment, where adjusted operating income surged to $3.041 billion and the medical benefit ratio improved to 84.6%, reflecting better government business performance and the absence of prior-year premium reserve charges. CVS’s vast scale—encompassing approximately 9,000 retail pharmacies, over 1,000 clinics, 88 million PBM members, and 37 million health insurance members—translated into strong cash flow, with net operating cash of $4.249 billion, underpinning a 22.8% stock price increase since reporting and a current trading price near $99.
Centene also impressed investors with a 7.1% revenue growth to $49.94 billion, surpassing analyst expectations by 6.2%, which propelled its stock price up 39.2% to $60.55. This performance underscores Centene’s ability to capitalize on market opportunities and maintain investor confidence amid a competitive landscape. In contrast, Cencora struggled to meet revenue expectations despite a 3.8% year-over-year increase to $78.36 billion, leading to a roughly 10% stock decline as investors reacted to the shortfall and uncertainty about future momentum.
Cigna’s Q1 results presented a paradox: while it posted solid revenue growth of 4.7% to $68.52 billion and earnings beats, its stock declined by 3.8%, trading around $281.15, as investor expectations outpaced analyst estimates. This disconnect highlights the market’s nuanced response to earnings quality versus growth prospects. Meanwhile, Progyny, despite modest revenue growth of 1.4% to $328.5 million, delivered the strongest forward guidance among peers, sparking a 35.3% surge in its stock price to $25.93, illustrating how future outlook can outweigh current scale in driving investor enthusiasm.
